Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.
Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...
More than 1,500 people who have sought support from the vaccine damage payment scheme after being injured or bereaved as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback